Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran

(2018) Jeffrey Weitz et al.   CANADIAN JOURNAL OF CARDIOLOGY

Prices of Generic Drugs Associated with Numbers of Manufacturers

(2017) Chintan V. Dave et al.   NEW ENGLAND JOURNAL OF MEDICINE

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients

(2016) Anuj Shah et al.   STROKE

What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs

(2015) Suzanne S. Dunne et al.   BMC Medicine

Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study

(2015) Maja Hellfritzsch et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

(2014) Jonathan Douxfils et al.   Journal of the American Heart Association

A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation

(2012) Stephen Andrew LaHaye et al.   EUROPEAN HEART JOURNAL

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy

(2012) Michiel Coppens et al.   EUROPEAN HEART JOURNAL

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study

(2012) Christian Torp-Pedersen et al.   THROMBOSIS AND HAEMOSTASIS

A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery

(2012) Thorsten Lehr et al.   THROMBOSIS AND HAEMOSTASIS

Hemorrhagic and Thrombotic Events Associated with Generic Substitution of Warfarin in Patients with Atrial Fibrillation: A Retrospective Analysis

(2011) Sameer R Ghate et al.   ANNALS OF PHARMACOTHERAPY

Brand Name versus Generic Warfarin: A Systematic Review of the Literature

(2011) Francesco Dentali et al.   PHARMACOTHERAPY

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)

(2010) L. Samuel Wann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration

(2009) Barbara M Davit et al.   ANNALS OF PHARMACOTHERAPY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE